Sirolimus to replace calcineurin inhibitors? Too early yet

Lancet. 2009 Apr 11;373(9671):1235-6. doi: 10.1016/S0140-6736(09)60709-1.
No abstract available

Publication types

  • Review

MeSH terms

  • Calcineurin Inhibitors*
  • Cyclosporine / therapeutic use
  • Graft Rejection / prevention & control
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / immunology
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation* / adverse effects
  • Kidney Transplantation* / immunology
  • Mycophenolic Acid / analogs & derivatives
  • Mycophenolic Acid / therapeutic use
  • Patient Selection
  • Protein Kinases / drug effects
  • Risk Factors
  • Sarcoma, Kaposi / drug therapy*
  • Sarcoma, Kaposi / etiology
  • Sirolimus / adverse effects
  • Sirolimus / immunology
  • Sirolimus / therapeutic use*
  • TOR Serine-Threonine Kinases
  • Transplantation Immunology / drug effects
  • Treatment Outcome

Substances

  • Calcineurin Inhibitors
  • Immunosuppressive Agents
  • Cyclosporine
  • Protein Kinases
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Mycophenolic Acid
  • Sirolimus